Found "Early HTA": 383 results
Sort by
Relevance

Quality of life after great saphenous vein ablation in Thai patients with great saphenous vein reflux (2015)

Boonying Siribumrungwong , Pinit Noorit , Chumpon Wilasrusmee, Yot Teerawattananon, Ammarin Thakkinstian Summary Background/Objective To determine the quality of life (QoL) in Thais after intervention for great saphenous vein (GSV) reflux. Methods Patients with Clinical Etiologic Anatomic

Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand (2015)

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Improving quality of primary care through financial incentives: the case of Thailand. (2016)

Improving quality of primary care through financial incentives: the case of Thailand. Paramjit Gill1, Rachel Foskett-Tharby1, Francoise Cluzeau2, Sripen Tantivess3 and Yot Teerawattananon3 1National Collaborating Centre for Indicator Development, University of Birmingham, UK 2NICE International

An ex-ante economic evaluation of the Maternal and Child Health Voucher Scheme as a decision-making tool in Myanmar (2016)

Pritaporn Kingkaew1,*, PitsaphunWerayingyong1, San San Aye2, Nilar Tin3, Alaka Singh4, Phone Myint2 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand, 2Department of Health Planning and 3Department of He

Maternal and child health voucher scheme in Myanmar: a review of early stage implementationv (2016)

Songyot Pilasant1, Wantanee Kulpeng1, Pitsaphun Werayingyong1*, Nattha Tritasavit1, Inthira Yamabhai1, Yot Teerawattananon1, Sangay Wangmo2 and Sripen Tantivess1 Abstract Background: The Maternal and Child Health Voucher Scheme (MCHVS) was introduced in Myanmar to address the high rate of mat

Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

Using an experiment among clinical experts to determine the cost and clinical impact of rapid whole exome sequencing in acute pediatric settings

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

Mapping the value for money of precision medicine: a systematic literature review and meta-analysis

About the study Objective: This study aimed to quantify heterogeneity in the value for money of precision medicine (PM) by application types across contexts and conditions and to quantify sources of heterogeneity to areas of particular promises or concerns as the field of PM moves forward. Methods

Research Proposal: Economic evaluation of an integrated care on delaying chronic kidney disease progression in rural communities of Thailand

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht f

Should high-cost bevacizumab be used for metastatic-colorectal cancer (mCRC) treatment in JKN in Indonesia?

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca
10 / Page